UniQure Shares Drop After FDA Shifts Stance On Huntington’s Gene Therapy Data

All NewsNovember 3, 2025

UniQure shares fell after the FDA questioned the adequacy of data supporting its AMT-130 gene therapy for Huntington’s disease, delaying BLA plans.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent